Skip to main content
NCBI home page
Critical Care logoLink to Critical Care
letter
. 2019 Jun 27;23:233. doi: 10.1186/s13054-019-2507-5

Is interleukin-8 a true predictor of pediatric acute respiratory distress syndrome outcomes? Beware of potential confounders

Sébastien Redant 1, François Angoulvant 2, Oceane Barbance 1, David De Bels 1, Andrea Gallerani 1, Rachid Attou 1, Kianoush Kashani 3, Patrick M Honore 1,✉
PMCID: PMC6595614  PMID: 31248436

We enthusiastically read the study by Flori et al. related to the potential association of interleukin-8 (IL8) with the outcomes of pediatric acute respiratory distress syndrome (PARDS) following respiratory tract infection. In this study, IL-8 found to be associated with mortality, duration of ventilation, pediatric intensive care unit (PICU) length of stay, and the degree of pulmonary morbidity, measured by oxygenation defect. Meanwhile, IL8 was not found to be associated with the occurrence of PARDS, per se [1]. Samransamruajkit et al. previously in a single-center study reported an association between mortality in PARDS and IL-8 levels (1288.7 ± 638 among non-survivors vs. 257 ± 366 pg/ml in survivors, P = .001) [2]. IL-8 is secreted by the lung endothelial cells in response to injury induced by infections or toxins. IL-8 concentration in bronchoalveolar lavage was found to be 5 to 10 times higher in the day of intubation when compared with control subjects. This indicates a substantial inflammation which leads to an increase of intra-alveolar neutrophils [3]. Hall et al. showed a significant association between IL-8 levels and respiratory infection with the H1N1 virus. IL8 levels in these patients were significantly higher when compared with other influenza subtypes (median of 55(13–201) vs. 0(0–13) pg/mL; P < .0001) [4]. A similar observation was made for Staphylococcus aureus in comparison with other microorganisms (164(52–4424) vs. 6.1(0–22) pg/ml; P = .0002) [4]. On the other hand, the PARDS-associated mortality rate is different based on the type of infection [5]. Hence, it would be reasonable to be cautious in the extrapolation of the knowledge related to PARDS-associated mortality when it is due to RSV versus PARDS-associated death in other infections [5]. Since the type of microorganism or virus influences the IL-8 level and PARDS outcome, we suggest the relationship of the IL-8 concentration and PARDS outcomes be stratified based on the type of causing microorganism or virus.

Acknowledgements

None.

Abbreviations

IL8

Interleukin-8

PARDS

Pediatric acute respiratory distress syndrome

PICU

Pediatric intensive care unit

RSV

Respiratory syncytial virus

Authors’ contributions

SR, KK, and PMH conceived the paper. All authors participated in drafting and reviewing. All authors read and approved the final version of the manuscript.

Funding

None.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Footnotes

This comment refers to the article available at 10.1186/s13054-019-2342-8

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Flori H, Sapru A, Quasney MW, Gildengorin G, Curley MAQ, Matthay MA, et al. A prospective investigation of interleukin-8levels in pediatric acute respiratory failure and acute respiratory distress syndrome. Crit Care. 2019;23:128. doi: 10.1186/s13054-019-2342-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Samransamruajkit R, Jiraratanawong K, Siritantiwat S, Chottanapan S, Deelodejanawong J, Sritippayawan S, et al. Potent inflammatory cytokine response following lung volume recruitment maneuvers with HFOV in pediatric acute respiratory distress syndrome. Asian Pac J Allergy Immunol. 2012;30(3):197–203. [PubMed] [Google Scholar]
  • 3.Todd DA, Marsh MJ, George A, Henderson NG, Barr H, Sebastian S, et al. Surfactant phospholipids, surfactant proteins, and inflammatory markers during acute lung injury in children. Pediatr Crit Care Med. 2010;11(1):82–91. doi: 10.1097/PCC.0b013e3181ae5a4c. [DOI] [PubMed] [Google Scholar]
  • 4.Hall MW, Geyer SM, Guo CY, Panoskaltsis-Mortari A, Jouvet P, Ferdinands J, et al. Innate immune function and mortality in critically ill children with influenza: a multicenter study. Crit Care Med. 2013;41(1):224–236. doi: 10.1097/CCM.0b013e318267633c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Khemani RG, Smith LS, Zimmerman JJ, Erickson S, Pediatric Acute Lung Injury Consensus Conference Group Pediatric acute respiratory distress syndrome: definition, incidence, and epidemiology: proceedings from the Pediatric Acute Lung Injury Consensus Conference. Pediatr Crit Care Med. 2015;16(5 Suppl 1):S23–S40. doi: 10.1097/PCC.0000000000000432. [DOI] [PubMed] [Google Scholar]
  • 6.Calfee Carolyn S, Delucchi Kevin L, Sinha Pratik, Matthay Michael A, Hackett Jonathan, Shankar-Hari Manu, McDowell Cliona, Laffey John G, O'Kane Cecilia M, McAuley Daniel F, Johnston Andrew J, Paikray Archana, Yates Cat, Polgarova Petra, Price Esther, McInerney Amy, Zamoscik Katarzyna, Dempsey Ged, Seasman Colette, Gilfeather Lynn, Hemmings Noel, O'Kane Sinead, Johnston Paul, Pokorny Lukas, Nutt Chris, O'Neill Orla, Prashast Prashast, Smalley Chris, Jacob Reni, O'Rourke James, Sultan Syed Farjad, Schilling Carole, Perkins Gavin D, Melody Teresa, Couper Keith, Daniels Ron, Gao Fang, Hull Julian, Gould Timothy, Thomas Matthew, Sweet Katie, Breen Dorothy, Neau Emer, Peel Willis J, Jardine Catherine, Jefferson Paul, Wright Stephen E, Harris Kayla, Thomas Matthew, Hierons Sarah, Laffey John, McInerney Veronica, Camporota Luigi, Lei Katie, Kaul Sundeep, Chibvuri Molly, Gratrix Andrew, Bennett Rachael, Martinson Victoria, Sleight Lisa, Smith Neil, Hopkins Philip A, Hadfield Daniel, Casboult Sarah, Wade-Smith Fiona, Dawson Julie, Mellis Clare, Harris Clair, Parsons Georgina, Helyar Sinead, Bodenham Andrew R, Elliot Stuart, Beardow Zoe, Birch Sian, Marsh Brian, Martin Teresa, Dhrampal Akesh, Rosbergen Melissa, Webb Stephen, Bottrill Fiona, Reschreiter Henrik, Barcraft-Barnes Helena, Camsooksai Julie, Johnston Andrew, Clarkson Aisling, Bentley Conor, Cooper Lauren, Qui Yongyan, Mitchell Natalie, Carrera Ronald, Whitehouse Arlo, Danbury Christopher M, Jacques Nicola, Brown Abby, Rogerson David, Morris Craig, Walsh Timothy, Gillies Mike, Price Grant, Kefala Kallirroi, Young Neil, Hope David, McCulloch Corrienne, Antonelli Jean, Ramsay Pam, Everingham Kirsty, Boardman Louise, Dawson Heidi, Pollock Fiona, Thompson Joanne, Welters Ingeborg D, Poole Lee, Hampshire Peter, Hall Alison, Williams Karen, Walker Anna, Youds Laura, Hendry Samantha, Waugh Victoria, Patrick-Heselton Julie, Shaw David, Chaudry Irfan, Baldwin Jacqueline, Drage Stephen, Ortiz-Ruiz de Gordoa Laura, McAuley Daniel, Bannon Leona, Quinn Vanessa, McNamee Lia, White Griania, Cecconi Maurizio, Mellinghoff Johannes, Ryan Donal, Nichol Alistair, Agarwal Banwari, Meale Paula, James Sarah, Dhadwal Kulwant, Martin Daniel, Walecka Agnieszka, Ward Stephen, Trinder John, Hagan Samantha, Montgomery Janice, Leonard Catherine, Lemon Elizabeth, Trinick Tom, Buddhavarapu Murthy, Ward Geraldine, Bassford Christopher, Davidson Alan, McGuigan Kate, Benchiheub Anissa, Hickey Naomi, Binning Alexander, Henderson Steven, Wood J A, Burtenshaw Andrew J, Kelly Dawn, Martin Terry, Thrush Jessica, Wollaston Julie, Graystone Stephen, Nicol Gavin, Sellors Gareth. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. The Lancet Respiratory Medicine. 2018;6(9):691–698. doi: 10.1016/S2213-2600(18)30177-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Zinter MS, Orwoll BE, Spicer AC, et al. Incorporating inflammation into mortality risk in pediatric acute respiratory distress syndrome. Crit Care Med. 2017;45:858–866. doi: 10.1097/CCM.0000000000002370. [DOI] [PMC free article] [PubMed] [Google Scholar]
Crit Care. 2019 Jun 27;23:233.

Authors’ response

Heidi Flori, Mary K Dahmer

We appreciate the insightful commentary by Dr. Redant and colleagues on our publication demonstrating that IL-8 is associated with poor outcome in children with severe acute respiratory failure, many of which had pediatric acute respiratory distress syndrome (PARDS) [1]. Indeed, it is important for research to generate the “next questions” to investigate. This is particularly true for understanding which biological markers may be impacted by individual disease processes, types of infection, host response characteristics, etc. Such understanding is the impetus behind the “precision medicine” movement.

Dr. Redant et al. suggest that analysis of the relationship between IL-8 and outcomes be stratified by type of microorganism causing infection. However, as an ancillary study to a sedation management trial, we do not have detailed infectious agent data. As shown in the supplement, median IL-8 levels varied by primary diagnosis; sepsis patients had a higher median IL-8 than those with pneumonia or bronchiolitis. Although not reported in the paper, IL-8 is independently associated with the duration of mechanical ventilation (P < 0.0005, all days) after adjusting for age, PRISM-III, and primary diagnoses (pneumonia [37%], bronchiolitis [20%], sepsis [19%], asthma [10%], aspiration pneumonia [6%], and other [8%]). Since the group with sepsis likely has a higher proportion of bacterial infections, and those with bronchiolitis likely have a high proportion with viral infections, one might speculate that IL-8 is associated with poor outcome independent of a bacterial or viral etiology. However, analysis of microorganism-based subgroups would be a much “cleaner” way to examine that question, yet such a strategy is hampered by the size of pediatric cohorts. Although the BALI study is one of the largest multi-center cohorts of pediatric acute respiratory failure and PARDS patients, our subgroup analyses still suffered from low numbers, especially when adjusting for important covariates. We anticipate this is also true for most other PARDS cohorts.

In summary, we agree there is value in stratifying analyses of IL-8 and outcomes by an infectious agent, which would demonstrate whether IL-8 is associated with outcome irrespective of underlying etiology, or, alternatively, varies by infectious agent. The use of a common set of data elements in PARDS-related studies may allow this question to be addressed in the future by combining datasets from multiple studies. Nonetheless, IL-8 remains an intriguing biomarker of inflammation in critical illness where it may be useful for stratification into endotypes [6] allowing predictive and prognostic enrichment for trials, and/or as a marker of disease trajectory with regard to response to therapy [7].

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Data Availability Statement

    Not applicable.

    Articles from Critical Care are provided here courtesy of BMC

    RESOURCES